Generate Biomedicines, Inc. Common Stock (GENB)vsBeiGene, Ltd. (ONC)
GENB
Generate Biomedicines, Inc. Common Stock
$15.30
-0.78%
HEALTHCARE · Cap: $1.97B
ONC
BeiGene, Ltd.
$297.49
+0.12%
HEALTHCARE · Cap: $33.06B
Smart Verdict
WallStSmart Research — data-driven comparison
BeiGene, Ltd. generates 16653% more annual revenue ($5.34B vs $31.89M). ONC leads profitability with a 5.4% profit margin vs 0.0%. ONC earns a higher WallStSmart Score of 42/100 (D).
GENB
Avoid16
out of 100
Grade: F
ONC
Hold42
out of 100
Grade: D
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for GENB.
Margin of Safety
+79.7%
Fair Value
$1726.48
Current Price
$297.49
$1428.99 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
No standout strengths identified
Revenue surging 32.8% year-over-year
Conservative balance sheet, low leverage
Areas to Watch
0.0% revenue growth
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
0.0% earnings growth
ROE of 7.5% — below average capital efficiency
5.4% margin — thin
Premium valuation, high expectations priced in
Comparative Analysis Report
WallStSmart ResearchBull Case : GENB
GENB has a balanced fundamental profile.
Bull Case : ONC
The strongest argument for ONC centers on Revenue Growth, Debt/Equity. Revenue growth of 32.8% demonstrates continued momentum.
Bear Case : GENB
The primary concerns for GENB are Revenue Growth, EPS Growth, Market Cap.
Bear Case : ONC
The primary concerns for ONC are EPS Growth, Return on Equity, Profit Margin. A P/E of 120.4x leaves little room for execution misses.
Key Dynamics to Monitor
GENB profiles as a value stock while ONC is a hypergrowth play — different risk/reward profiles.
ONC is growing revenue faster at 32.8% — sustainability is the question.
ONC generates stronger free cash flow (131M), providing more financial flexibility.
Monitor BIOTECHNOLOGY industry trends, competitive dynamics, and regulatory changes.
Bottom Line
ONC scores higher overall (42/100 vs 16/100) and 32.8% revenue growth. Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Generate Biomedicines, Inc. Common Stock
HEALTHCARE · BIOTECHNOLOGY · USA
Generate Biomedicines, Inc. is an innovative biotechnology company focused on harnessing the power of genetic engineering to develop protein therapeutics for a range of diseases. By leveraging advanced artificial intelligence and machine learning technologies, Generate Biomedicines aims to streamline the drug discovery process, significantly reducing time and costs associated with traditional methods. The company's proprietary platform enables the rapid design and optimization of therapeutic proteins, positioning it at the forefront of the biopharmaceutical industry. With a strong commitment to improving patient outcomes, Generate Biomedicines continues to expand its pipeline and collaborate with leading partners to bring transformative treatments to market.
BeiGene, Ltd.
HEALTHCARE · BIOTECHNOLOGY · USA
BeiGene, Ltd., an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. The company is headquartered in Camana Bay, the Cayman Islands.
Visit Website →Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?